Close Menu

NEW YORK (GenomeWeb) – German firm Curetis has been granted de novo clearance by the US Food and Drug Administration for a multiplex assay to detect lower respiratory tract infections, as well as for the firm's molecular diagnostic platform, Unyvero. The assay is the first multiplex lower respiratory tract infection test to be cleared by the FDA, the firm noted in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.